BSE filing, NSE: KIMS. Summary written from the filing by ALFA Finder's alert engine.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹704.60
- Market cap
- ₹29,594 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 144.8×Sector 52.0×
- Promoter holding
- 32.66%+0.16% QoQ
- FII holding
- 15.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Legal & Regulatory
KIMS discloses a pending suit over its Chennai hospital land lease, naming it defendant. Supreme Court dismissed its SLP; no injunction halts the project.
Krishna Institute of Medical Sciences Board Meeting Date
KIMS Ltd informed exchanges of a Board Meeting on November 4, 2026 to approve Q2 and H1 unaudited results. Trading window closes until 48 hours post-disclosure.
Krishna Institute of Medical Sciences Other Announcement
The company filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
Krishna Institute of Medical Sciences Other Announcement
KIMS provided additional information regarding the board meeting held on October 06, 2026, in response to a BSE query.
Krishna Institute of Medical Sciences Acquisition Worth ₹75 Cr
KIMS will acquire a 51% stake in Insignia Healthcare Private Limited for ₹75 Crore as a strategic investment. This will occur in tranches over 24 months.
- Value
- ₹75.00 Cr
- Execution
- 12 to 24 Months
Krishna Institute of Medical Sciences Acquisition Worth ₹40 Cr
KIMS will acquire a 22% equity stake in Splendid Hospitals Private Limited for up to ₹40 Crore. This strategic investment will be executed via primary infusion.
- Value
- ₹40.00 Cr
- Execution
- On or before 31.03.2027
Other board meeting date announcements
All →RateGain Travel Technologies Board Meeting Date
RateGain Travel Technologies will hold a board meeting on 5 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window closes from 1 October 2026 until 48 hours after results.
Tapi Fruit Processing Board Meeting Date
Tapi Fruit Processing will hold a board meeting on November 3, 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from October 1 to November 5, 2026.
Parag Milk Foods Board Meeting Date
Parag Milk Foods has notified BSE of a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Trading window closure runs from 1 October to 5 November 2026.
Vedant Fashions Board Meeting Date
Vedant Fashions will hold a board meeting on 5 November 2026 to consider unaudited results for the quarter and half-year ended September 2026. The meeting is a prior intimation, so no results are approved yet.
Dangee Dums Board Meeting Date
Dangee Dums will hold a board meeting on 2 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. Trading window closure runs until 4 November 2026.
Relic Technologies Board Meeting Date
Relic Technologies intimated a board meeting on 2 Nov 2026 to consider unaudited standalone and consolidated Q2 results for the period ended 30 Sep 2026. The trading window closes from 1 Oct 2026 until 48 hours after the results are disseminated.